title: [Essential phospholipids in the treatment of chronic hepatitis B virus infection].
abstract: The authors investigated 24 patients with chronic infection with the hepatitis B virus. HBeAg-positive patients had significantly (alpha = 0.05) more frequently pathological initial values of biochemical and immunological indicators, as compared with anti-HBe-positive patients. Delta antigen in the liver and anti-delta antibodies in serum if examined, were always negative. All patients were subjected to 16-week treatment with Essentiale forte (Natterman). After treatment and after the subsequent 16 weeks in none of the patients loss of HBsAg or seroconversion of HBeAg-positive to anti-HBe-positive was recorded. In the sub-group of HBeAg-positive subjects after treatment a significant drop of gamma-globulins and circulating immunocomplexes occurred, in the sub-group of anti-HBe-positive subjects a significant rise of active and total T-lymphocytes was found. The authors recommend to test Essentiale forte in the prevention and treatment of immunocomplex disease in chronic infection with the hepatitis B virus.
authors.affiliation: Katedra internistických disciplín I. Lekárskej fakulty Univerzity Komenského, Bratislava.
authors.forename: I
authors.initials: I
authors.lastname: Hanták
authors.forename: M
authors.initials: M
authors.lastname: Boca
authors.forename: M
authors.initials: M
authors.lastname: Mikulecký
authors.forename: D
authors.initials: D
authors.lastname: Stancek
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000627:therapeutic use*
chemical_list: D010713:Phosphatidylcholines; C011246:essential 303 forte
vernacular_title: Esenciálne fosfolipidy v liecbe chronickej infekcie vírusom hepatitidy B.